These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
287 related articles for article (PubMed ID: 10393683)
21. Evidence that rapamycin rescue therapy delays rejection of major (MHC) plus minor (non-MHC) histoincompatible heart allografts in rats. Wang ME; Stepkowski SM; Ferraresso M; Kahan BD Transplantation; 1992 Oct; 54(4):704-9. PubMed ID: 1412762 [TBL] [Abstract][Full Text] [Related]
22. Inhibition of transplant vasculopathy is associated with attenuated host allo-antibody response. Maggard MA; Johnson C; Wang T; Terasaki P; Kupiec-Weglinski JW; Busuttil RW; Imagawa DK Transplant Proc; 1999; 31(1-2):728-9. PubMed ID: 10083311 [No Abstract] [Full Text] [Related]
23. Reversal of ongoing heart, kidney, and pancreas allograft rejection and suppression of accelerated heart allograft rejection in the rat by rapamycin. Chen H; Wu J; Xu D; Luo H; Daloze PM Transplantation; 1993 Sep; 56(3):661-6. PubMed ID: 8212164 [TBL] [Abstract][Full Text] [Related]
24. Rapamycin, mycophenolate mofetil, methylprednisolone, and cytotoxic T-lymphocyte-associated antigen 4 immunoglobulin-based conditioning regimen to induce partial tolerance to hind limb allografts without cytoreductive conditioning. Pan H; Wang L; Zhang X; Zhang G; Mai H; Han Y; Guo S Transplant Proc; 2008 Jun; 40(5):1714-21. PubMed ID: 18589179 [TBL] [Abstract][Full Text] [Related]
25. Synergistic interaction of 3 M KCl-extracted donor antigens (e-HAg) with cyclosporine or cyclosporine/sirolimus for prolongation of rat heart allograft survival. Hamashima T; Stepkowski SM; Chou TC; Kahan BD Transpl Immunol; 1995 Dec; 3(4):335-41. PubMed ID: 8665153 [TBL] [Abstract][Full Text] [Related]
26. 15AU81, a prostacyclin analog, enhances donor-specific hepatocytes to prolong the survival of rat heart but not small bowel allografts. Boyle MJ; Dumble LJ Cell Transplant; 1999; 8(5):543-8. PubMed ID: 10580348 [TBL] [Abstract][Full Text] [Related]
27. Cyclosporine treatment of high dose and long duration reduces the severity of graft coronary artery disease in rodent cardiac allografts. Lijkwan MA; Cooke DT; Martens JM; Kown MH; Murata S; Peterson SH; Hoyt EG; Robbins RC J Heart Lung Transplant; 2005 Apr; 24(4):439-45. PubMed ID: 15797746 [TBL] [Abstract][Full Text] [Related]
28. Rapamycin is less fibrogenic than Cyclosporin A as demonstrated in a rat model of chronic allograft nephropathy. Luo L; Sun Z; Luo G J Surg Res; 2013 Jan; 179(1):e255-63. PubMed ID: 22480837 [TBL] [Abstract][Full Text] [Related]
29. Effect of a short course of rapamycin, cyclosporin A, and donor-specific transfusion on rat cardiac allograft survival. Davies CB; Madden RL; Alexander JW; Cofer BR; Fisher RA; Anderson P Transplantation; 1993 May; 55(5):1107-12. PubMed ID: 8497890 [TBL] [Abstract][Full Text] [Related]
30. Inhibition of host-versus-graft and graft-versus-host responses after small bowel transplantation in rats by rapamycin. Stepkowski SM; Chen HF; Wang ME; Daloze P; Kahan BD Transplantation; 1992 Feb; 53(2):258-64. PubMed ID: 1738917 [TBL] [Abstract][Full Text] [Related]
31. Viral serine proteinase inhibitor (SERP-1) effectively decreases the incidence of graft vasculopathy in heterotopic heart allografts. Hausen B; Boeke K; Berry GJ; Morris RE Transplantation; 2001 Aug; 72(3):364-8. PubMed ID: 11502962 [TBL] [Abstract][Full Text] [Related]
32. Accelerated graft arteriosclerosis in cardiac transplants: complement activation promotes progression of lesions from medium to large arteries. Qian Z; Hu W; Liu J; Sanfilippo F; Hruban RH; Baldwin WM Transplantation; 2001 Sep; 72(5):900-6. PubMed ID: 11571457 [TBL] [Abstract][Full Text] [Related]
34. The contribution of terminal complement components to acute and hyperacute allograft rejection in the rat. Brauer RB; Baldwin WM; Ibrahim S; Sanfilippo F Transplantation; 1995 Jan; 59(2):288-93. PubMed ID: 7839453 [TBL] [Abstract][Full Text] [Related]
35. Inhibition of endothelin-1 improves survival and vasculopathy in rat cardiac transplants treated with cyclosporine. Simonson MS; Robinson AV; Schulak JA; Hricik DE Transplantation; 2002 Apr; 73(7):1054-9. PubMed ID: 11965031 [TBL] [Abstract][Full Text] [Related]
36. Histological characterization and pharmacological control of chronic rejection in xenogeneic and allogeneic heart transplantation. Shen J; Chong AS; Xiao F; Liu W; Huang W; Blinder L; Foster P; Sankary H; Jensik S; McChesney L; Mital D; Williams JW Transplantation; 1998 Sep; 66(6):692-8. PubMed ID: 9771831 [TBL] [Abstract][Full Text] [Related]
37. The significance of timing of additional short-term immunosuppression in the donor-specific transfusion/cyclosporine-treated rat. Levy AE; Alexander JW Transplantation; 1996 Jul; 62(2):262-6. PubMed ID: 8755826 [TBL] [Abstract][Full Text] [Related]
38. Humoral immunity in allograft rejection. The role of cytotoxic alloantibody in hyperacute rejection and enhancement of rat cardiac allografts. Oluwole SF; Tezuka K; Wasfie T; Stegall MD; Reemtsma K; Hardy MA Transplantation; 1989 Nov; 48(5):751-5. PubMed ID: 2815247 [TBL] [Abstract][Full Text] [Related]
39. Single dose anti-CD4 monoclonal antibody for induction of tolerance to cardiac allograft in high- and low-responder rat strain combinations. Qi Z; Riesbeck K; Ostraat O; Tufveson G; Ekberg H Transpl Immunol; 1997 Sep; 5(3):204-11. PubMed ID: 9402687 [TBL] [Abstract][Full Text] [Related]
40. Cytokines regulate the pattern of rejection and susceptibility to cyclosporine therapy in different mouse recipient strains after cardiac allografting. Wang H; Hosiawa KA; Min W; Yang J; Zhang X; Garcia B; Ichim TE; Zhou D; Lian D; Kelvin DJ; Zhong R J Immunol; 2003 Oct; 171(7):3823-36. PubMed ID: 14500684 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]